Emblem AI
↗San Francisco, USA
Emblem AI (operating as Emblem) is an AI-powered clinical evidence platform designed to transform how life sciences companies and legal professionals process medical data. The company leverages advanced machine learning and generative AI to automate the summarization of complex medical records, extract structured clinical data, and generate case-ready chronologies and evidence.
For the pharmaceutical and biotechnology sectors, Emblem's platform accelerates the generation of clinical evidence from real-world data (RWD), supporting regulatory submissions, safety monitoring, and market access. By reducing the time required to analyze thousands of pages of patient records from days to hours, the company enables faster decision-making in clinical development and post-market surveillance.
CLASSIFICATION
Company Type:Digital Health
Therapeutic Areas:
Industry:Digital Health
Sub-Industry:AI for Life Sciences / Clinical Evidence
SIZE & FINANCIALS
Employees:1-50
Revenue:$1M-$5M
Founded:2023
Ownership:private
Status:operating
FUNDING
Stage:Seed/Series A
Total Raised:$5M-$15M (estimated based on founder profile)
Investors:Undisclosed (likely top-tier Silicon Valley VCs)
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (Platform)
Modalities:AI Platform, SaaS, Real-World Evidence (RWE)
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Collaborations with CROs and medical-legal firms for data processing
COMPETITION
Position:Emerging
Competitors:Unlearn.AI, QuantHealth, Aetion, InQuery, One Zyme
LEADERSHIP
Key Executives:
Ram Vemuri - CEO
Scientific Founders:Ram Vemuri
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Emblem AI. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.